Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
Based On Veteran Researcher’s Innovation
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
You may also be interested in...
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.